Moving Beyond Anti-Vascular Endothelial Growth Factor Therapy in Ovarian Cancer

被引：7
作者：
Sood, Anil K. [1 ]
Coleman, Robert L. [1 ]
Ellis, Lee M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
PHASE-II; TUMOR ANGIOGENESIS; BEVACIZUMAB; ANGIOPOIETIN-2; PACLITAXEL;
D O I：
10.1200/JCO.2011.38.8413
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：345 / 347
页数：3
相关论文
共 22 条
[1]   OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [J].
Aghajanian, C. ;
Finkler, N. J. ;
Rutherford, T. ;
Smith, D. A. ;
Yi, J. ;
Parmar, H. ;
Nycum, L. R. ;
Sovak, M. A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
[2]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[3]   Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J].
Azad, Nilofer S. ;
Posadas, Edwin M. ;
Kwitkowski, Virginia E. ;
Steinberg, Seth M. ;
Jain, Lokesh ;
Annunziata, Christina M. ;
Minasian, Lori ;
Sarosy, Gisele ;
Kotz, Herbert L. ;
Premkumar, Ahalya ;
Cao, Liang ;
McNally, Deborah ;
Chow, Catherine ;
Chen, Helen X. ;
Wright, John J. ;
Kohn, Elise C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3709-3714
[4]   Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study [J].
Burger, R. A. ;
Brady, M. F. ;
Bookman, M. A. ;
Walker, J. L. ;
Homesley, H. D. ;
Fowler, J. ;
Monk, B. J. ;
Greer, B. E. ;
Boente, M. ;
Liang, S. X. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[5]   Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study [J].
Burger, Robert A. ;
Sill, Michael W. ;
Monk, Bradley J. ;
Greer, Benjamin E. ;
Sorosky, Joel I. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5165-5171
[6]   Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON? [J].
Burstein, Harold J. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) :1232-1235
[7]   Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [J].
Cannistra, Stephen A. ;
Matulonis, Ursula A. ;
Penson, Richard T. ;
Hambleton, Julie ;
Dupont, Jakob ;
Mackey, Howard ;
Douglas, Jeffrey ;
Burger, Robert A. ;
Armstrong, Deborah ;
Wenham, Robert ;
McGuire, William .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5180-5186
[8]   Phase II Trials in Journal of Clinical Oncology [J].
Cannistra, Stephen A. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3073-3076
[9]   Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas [J].
Chae, Sung-Suk ;
Kamoun, Walid S. ;
Farrar, Christian T. ;
Kirkpatrick, Nathaniel D. ;
Niemeyer, Elisabeth ;
de Graaf, Annemarie M. A. ;
Sorensen, A. Gregory ;
Munn, Lance L. ;
Jain, Rakesh K. ;
Fukumura, Dai .
CLINICAL CANCER RESEARCH, 2010, 16 (14) :3618-3627
[10]   At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis [J].
Cohn, David E. ;
Kim, Kenneth H. ;
Resnick, Kimberly E. ;
O'Malley, David M. ;
Straughn, J. Michael, Jr. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) :1247-1251
123